Novasep enhances HPAPI manufacturing know-how
Expansion establishes role it plays in the oncology sector, company suggests
Novasep, a supplier of services and technologies for the life sciences industry, has increased its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans site in France.
As a contract development and manufacturing organization (CDMO), the decision to expand illustrates clients' confidence in Novasep’s knowledge in HPAPIs and antibody drug conjugates (ADCs), but also highlights the role Novasep plays in the production of targeted molecules to treat cancer, the company says.
The Le Mans location has forged partnerships with big pharma, along with new collaborations with the biotech industry. To support this growth and sustain the increase in both clinical and commercial production capacity, Novasep is in the process of hiring more than 30 people for this site, alongside an investment of more than $4.8 million.
